DCM
AIMT

Driehaus Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Driehaus Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-64,315
Closed -$1.63M – 672
2015
Q3 		$1.63M Buy
+64,315
New +$1.5M 0.06% 300

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Driehaus Capital Management's AIMT Position: Q4 2015 in Review

Driehaus Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2015, closing a stake of 64,315 shares — an estimated $1.63M sold.

Driehaus Capital Management first reported a position in AIMT in Q3 2015 and held it in 1 quarter. The position peaked at $1.63M in Q3 2015. 58 funds tracked by Wall St. Rank hold AIMT as of Q4 2015.

  • Driehaus Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Driehaus Capital Management sold 64,315 Aimmune Therapeutics shares in Q4 2015, an estimated $1.63M.
  • Driehaus Capital Management first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 1 quarter.
  • Driehaus Capital Management's Aimmune Therapeutics position peaked at $1.63M in Q3 2015.
  • 58 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2015.

Based on Driehaus Capital Management's 13F filing for Q4 2015, filed 12 Feb 2016.